Class: Parasympathomimetic (Cholinergic) Agents
VA Class: AU300
CAS Number: 101-26-8
Brands: Mestinon, Regonol
- Military Use for Soman Poisoning Prophylaxis
Use of pyridostigmine alone is not protective against soman effects.111 Efficacy depends on rapid use of nerve agent antidotes (i.e., atropine and pralidoxime) following nerve agent exposure.111
Protective garments (e.g., masks, hoods, overgarments) specifically designed for protection from chemical nerve agents are the primary means of protection against nerve agent exposure; do not rely solely on pretreatment with pyridostigmine, atropine, and pralidoxime to provide complete protection.111
Do not administer pyridostigmine after soman exposure.111 Discontinue at first sign of nerve agent poisoning; may exacerbate effects of a sublethal exposure.111
- Experience of Health Care Personnel
Pyridostigmine should be administered by IV injection only by adequately trained individuals familiar with the drug’s actions, characteristics, and risks.124
Introduction
Reversible anticholinesterase agent.a 123 124 111
Uses for Pyridostigmine Bromide
Myasthenia Gravis
Symptomatic management of myasthenia gravis to improve muscle strength.a 123
Not effective in patients resistant to anticholinesterase drugs.a
Has been used parenterally (IV or IM) for symptomatic treatment of acute exacerbations of myasthenia gravis or when oral therapy was impractical.a However, the injectable preparation that was used for this indication no longer is commercially available in the US; the parenteral injection currently commercially available in the US does not include this use in its prescribing information.124
Surgery
Postoperative reversal of the effects of nondepolarizing neuromuscular blocking agents (e.g., gallamine, metocurine, tubocurarine [all no longer commercially available in the US], pancuronium).a 124
Not effective and should not be used for reversal of depolarizing neuromuscular blocking agents (e.g., succinylcholine, decamethonium).a
Chemical Warfare Agent Poisoning
Preexposure prophylaxis against lethal effects of soman nerve agent poisoning in military combat personnel.111 116
Used in conjunction with standard treatment of nerve agent poisoning (i.e., atropine and pralidoxime chloride) and other protective measures (e.g., masks, hoods, overgarments).111
Discontinue use at first indication of nerve agent poisoning.111 Not for use after exposure to soman; not expected to be effective after such exposure and may exacerbate effects of sublethal exposure.111 (See Military Use for Soman Poisoning Prophylaxis in Boxed Warning.)
Pyridostigmine Bromide Dosage and Administration
General
Myasthenia Gravis
Dosage, route, and frequency of administration depend on the requirements and clinical response of the patient.a Carefully individualize dosage according to individual requirements and response and minimize adverse effects by precise dosage adjustment.a
Dosage requirements may vary from day to day, according to remissions and exacerbations of the disease and the physical and emotional stress suffered by the patient.a
Treat mild exacerbations by increasing dosage under medical supervision as long as increase produces symptomatic improvement.a
Once stabilized on pyridostigmine, may teach patients how to recognize adverse muscarinic effects and self-modify dosage or take atropine, if necessary.a
Complete restoration of muscle strength is rare; do not attempt to relieve all symptoms by increasing dosage above maximum response level.a
Individual muscle groups respond differently to the same dose; may produce weakness in one while increasing strength in another.a Measure vital capacity whenever increasing dosage to ensure good respiratory function.a Have adequate facilities for CPR, cardiac monitoring, endotracheal intubation, and respiratory assistance available during dosage adjustment.a
Postoperative Reversal of Nondepolarizing Neuromuscular Blocking Agent Effects
Administer IV only by adequately trained individuals familiar with the actions, characteristics, and risks of pyridostigmine.124
Always have atropine and medications to treat shock readily available in case of hypersensitivity reaction.124
Give atropine sulfate or glycopyrrolate immediately prior to or concurrently with pyridostigmine when reversing the actions of nondepolarizing neuromuscular blocking agents to minimize pyridostigmine's adverse effects (e.g., excessive secretions, bradycardia).124
Monitor muscle twitch response to peripheral nerve stimulation; administer pyridostigmine after spontaneous recovery of neuromuscular function begins.124 Satisfactory reversal is evident by adequate voluntary respiration, respiratory measurements, and use of a peripheral nerve stimulator device.124
Patient must be well ventilated; maintain patent airway and manual or mechanical ventilation until complete recovery of normal respiration is assured.124 Recurrence of paralysis unlikely after satisfactory reversal attained.124
Chemical Warfare Agent Poisoning
Administer orally prior to an expected exposure to soman (i.e., when under the threat of a nerve agent attack).111 Do not take after exposure to soman.111
If taken immediately before or at the same time as soman poisoning, pyridostigmine is not likely to be effective and may exacerbate the effects of a sublethal exposure.111
Administration
Administer orally or by very slow IV injection.a Also has been administered by IM injection,a 125 but manufacturer of currently available injectable preparation states that this injection is for IV injection only.124
Oral Administration
Administer orally, adjusting frequency and timing of administration according to individual response.a
Oral solution may be useful for children and patients who have difficulty swallowing or who require precise dosage adjustments not possible with tablets.a 123 g
Some clinicians recommend that extended-release tablets be used only at bedtime for patients who are very weak upon awakening.a May use extended-release tablets concurrently with conventional tablets or syrup to achieve optimum control.123
NG Tube
May administer oral solution through nasogastric tube.a
IV Administration
For solution and drug compatibility information, see Compatibility under Stability.
Administer by very slow IV injection.a (See General under Dosage and Administration.)
Dosage
Pediatric Patients
Myasthenia Gravis
Oral
Neonates: 5 mg every 4–6 hours.a 125 Gradually reduce daily dosage until drug can be withdrawn.a (See Pediatric Use under Cautions.)
Children: 7 mg/kg daily administered in 5–6 divided doses.a 125 (See Pediatric Use under Cautions.)
IV or IM
Neonates: 0.05–0.15 mg/kg (maximum single IV or IM dose of 10 mg) every 4–6 hours.a 125 Gradually reduce daily dosage until drug can be withdrawn.a (See Pediatric Use under Cautions.)
Children: 0.05–0.15 mg/kg (maximum single IV or IM dose of 10 mg) every 4–6 hours.125
Adults
Myasthenia Gravis
Oral
Initially, 60 mg 3 times daily or dosage smaller than that required to produce maximum strength.a May gradually increase as needed at intervals ≥48 hours.a
Adjust dosage of conventional tablets or syrup for treatment of myasthenia gravis so larger doses are taken at times of greatest fatigue (e.g., 30–45 minutes before meals to assist patients who have difficulty eating).a 123
Usual daily maintenance dosage is 60–1500 mg (average 600 mg).a 123
Extended-release tablets: 180–540 mg 1–2 times daily (with ≥6 hours between doses).a 123 However, some clinicians recommend use of extended-release tablets only at bedtime for patients who are very weak upon awakening.a
Oral dosage changes may take several days to produce results.a When a further increase in dosage produces no corresponding increase in muscle strength, reduce dosage to the previous level.a
Dosage requirements may vary from day to day.a
Oral dosage requirements are approximately 30 times parenteral dosage requirements.a
IV or IM
Give 1/30 usual oral dose.a
Observe closely for cholinergic reactions.a
Surgery
Reversal of Nondepolarizing Neuromuscular Blocking Agent Effects
IV
0.1–0.25 mg/kg.124 Give concurrently with or immediately after 0.6–1.2 mg IV atropine sulfate a 124 or an equipotent dose of glycopyrrolate.124
Full recovery usually occurs within 15 minutes but may require ≥30 minutes.124
Additional doses of pyridostigmine not recommended if reversal is inadequate; instead, manage with manual or mechanical ventilation until adequate recovery occurs.124
Chemical Warfare Agent Poisoning
Preexposure Prophylaxis for Soman Poisoning
Oral
30 mg every 8 hours beginning several hours prior to anticipated exposure.111
Discontinue at first sign of nerve agent poisoning; immediately treat with atropine and pralidoxime.111
Effects of use for >14 consecutive days not established; evaluate continuation of prophylaxis based on likelihood of exposure to soman.111
Special Populations
Hepatic Impairment
No specific dosage recommendations at this time.111 a 123 124
Renal Impairment
Lower dosages may be required; carefully titrate dosage.a 123
Geriatric Patients
Careful dosage selection recommended due to possible age-related decrease in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.111
Pregnant Women
Myasthenia Gravis
Labor and Delivery: An IM or slow IV injection of 1/30 the usual oral dose has been administered 1 hour before completion of the second stage of labor.a
Cautions for Pyridostigmine Bromide
Contraindications
Known hypersensitivity to anticholinesterase agents.111 a 124
Mechanical obstruction of the intestinal or urinary tract.a 111 123 124
Warnings/Precautions
Warnings
Cholinergic Crisis
Overdosage may result in cholinergic crisisa 123 (e.g., excessive salivation and sweating, miosis, nausea, vomiting, diarrhea, bradycardia or tachycardia, hypotension or hypertension, confusion, seizures, coma, severe muscle weakness, paralysis);a may result in death.123 If overdosage occurs, maintain adequate respiration and give IV atropine.a
Myasthenic crisis due to increased disease severity also causes extreme muscle weakness; symptomatic differentiation from cholinergic crisis may be difficult.a 123 Time to onset of symptoms approximately 1 hour after dose suggests overdosage, while ≥3 hours after dose suggests underdosage or resistance is the more likely diagnosis.a May require use of edrophonium chloride for the differential diagnosis.a 123
If severe cholinergic reaction occurs, discontinue pyridostigmine immediately and institute appropriate therapy as indicated (e.g., atropine, medications to treat shock).a 124
Excessive IV doses may produce depolarization block when administered at doses above therapeutic range to reverse nondepolarizing neuromuscular blocking agent effects.124 Therapeutic index (ratio of reversal dose to blocking dose) is approximately 1:6.124
Concomitant Diseases
Use with caution in patients with bronchial asthma, COPD, bradycardia, or cardiac arrhythmias.a 124 111
Preexposure Prophylaxis for Soman Poisoning
Do not administer pyridostigmine after soman exposure.111 Discontinue at first sign of nerve agent poisoning; may exacerbate effects of a sublethal soman exposure.111 (See Boxed Warning.)
Military personnel experiencing severe adverse effects (e.g., difficulty breathing, severe dizziness, loss of consciousness) associated with pyridostigmine use should temporarily discontinue the drug and immediately seek medical care.111
Sensitivity Reactions
Bromide Sensitivity
Use caution in patients with known bromide sensitivity.111
May cause skin rash, which usually disappears when pyridostigmine bromide is discontinued.a 111 123 124
General Precautions
Electrolyte Imbalance
Conditions resulting in electrolyte imbalance (e.g., adrenocortical insufficiency) may alter neuromuscular blockade (enhance or inhibit) and interfere with postoperative restoration of neuromuscular function by pyridostigmine.124
Specific Populations
Pregnancy
Category C (injection, oral solution, and tablets [except 30-mg tablets for military use]).124 Risk of uterine irritability and induction of premature labor if anticholinesterase agents are given IV near term.a
Category B (30-mg tablets for military use only).111
Lactation
Not known whether pyridostigmine is distributed into milk.111 Caution advised if used in nursing women.111
Pediatric Use
Safety and efficacy not established.109 111 124
Pyridostigmine bromide injection contains 1% benzyl alcohol.124 Manufacturer does not recommend use in neonates;124 AAP states that the presence of small amounts of this preservative in a commercially available injection should not proscribe its use when indicated in neonates.103 Consider combined daily intake of benzyl alcohol from all sources.124
Geriatric Use
Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults; select dosage with caution.111
Substantially eliminated by the kidneys; may be useful to monitor renal function since geriatric patients are more likely to have decreased renal function.111
Renal Impairment
Use with caution.111 Clearance may be decreased; dosage adjustments necessary in renal disease. (See Renal Impairment under Dosage and Administration.)109 111
Common Adverse Effects
Diarrhea,111 abdominal pain or cramps,111 116 dysmenorrhea,111 increased flatus,116 nausea,116 urinary urgency and frequency.116
Interactions for Pyridostigmine Bromide
Specific Drugs
Drug | Interaction | Comments |
|---|---|---|
4-Aminopyridine (not commercially available in the US) | Possible delayed onset of IV pyridostigmine124 | |
Aminoglycosides (e.g., gentamicin, kanamycin, neomycin, streptomycin) | Possible prolongation of neuromuscular blockade or resistance to reversal if used in conjunction with nondepolarizing neuromuscular blocking agents124 | Use cautiously, if at all111 |
Anesthetics, local or general | Interfere with neuromuscular transmissiona | Use cautiously, if at alla |
Antiarrhythmic agents | Interfere with neuromuscular transmissiona | Use cautiously, if at alla |
Atropine | Antagonizes muscarinic effects of pyridostigminea 111 | Interaction used to therapeutic advantage to counteract muscarinic symptoms of pyridostigmine toxicity; however,111 atropine also may mask manifestations of pyridostigmine overdose and prevent early detection of cholinergic crisisa 123 |
Bacitracin | Possible prolongation of neuromuscular blockade or resistance to reversal if used in conjunction with nondepolarizing neuromuscular blocking agents124 | |
β-Adrenergic blocking agents | Possible additive bradycardiae Possible inhibition of pyridostigmine efficacy in myasthenia gravise | Use concomitantly with caution; 111 effects on patients with borderline heart failure or AV conduction disturbances not determined118 |
Dexpanthenol | Converted to pantothenic acid in vivo; possible additive effects due to increased acetylcholine productiona 111 | |
Magnesium salts | Possible enhanced neuromuscular blockade124 | Consider possibility of interference with restoration of neuromuscular function by pyridostigmine124 |
Mefloquine | Possible additive GI effects111 Possible additive effects on atrial rate111 | |
Miotics, topical (e.g., physostigmine) | Possible additive effects; may cause or exacerbate problems with night visiona 111 | |
Neuromuscular blocking agents, depolarizing (e.g., succinylcholine) | Possible enhanced and/or prolonged neuromuscular blockade111 a | Do not use for reversal of depolarizing neuromuscular blockadea Use caution in soldiers who received pyridostigmine if depolarizing agent administered during surgery111 117 |
Neuromuscular blocking agents, nondepolarizing (e.g., tubocurarine, metocurine, gallamine [all no longer commercially available in the US], pancuronium) | Antagonism of nondepolarizing muscle relaxant effectsa | Interaction used to therapeutic advantage to reverse muscle relaxation induced by neuromuscular blocking agents after surgerya May need to increase dosage of nondepolarizing agent in soldiers who received pyridostigmine111 |
Opiate agonists | Possible exacerbation of pyridostigmine-induced bradycardia111 | |
Polymyxins (e.g., colistin, polymyxin B, sodium colistimethate) | Possible prolongation of neuromuscular blockade or resistance to reversal if used in conjunction with nondepolarizing neuromuscular blocking agents124 | |
Quinidine | Recurrent paralysis may occur if used in conjunction with nondepolarizing neuromuscular blocking agents124 | |
Tetracyclines | Possible prolongation of neuromuscular blockade or resistance to reversal if used in conjunction with nondepolarizing neuromuscular blocking agents124 |
Pyridostigmine Bromide Pharmacokinetics
Absorption
Bioavailability
Poorly absorbed from GI tract following oral administration;a bioavailability is 10–20%.101 111 115
Peak plasma concentrations occur 2.2 hours after oral ingestion of a 30-mg dose as conventional tablet.111
Extended-release tablets reportedly release one-third of total dose immediately, then remainder over 8–12 hours; however, release may be erratic and unpredictable.a
Onset
Following oral administration in patients with myasthenia gravis, 30–45 minutes.a
Following IV injection in patients with myasthenia gravis, muscle strength increased in 2–5 minutes.a
When used for postoperative reversal of nondepolarizing neuromuscular blocking agent effects, time to peak effect is dose-dependent; with 0.25-mg/kg dosage, return of twitch height to 90% of control occurs within about 6 minutes.124 At lower dosages, full recovery usually occurs within 15 minutes; may require ≥30 minutes in some patients.124
Duration
Duration of effects varies in patients with myasthenia gravis.a Effects generally persist for 3–6 hours for conventional oral tablets, about 8–12 hours for extended-release tablets, and about 2–3 hours for IV injection.a
Distribution
Extent
Distributed into most tissues, except brain, intestinal wall, fat, and thymus.a
Crosses the placenta;a not known whether distributed into milk.a 111
Elimination
Metabolism
Metabolized via hydrolysis by cholinesterases and by microsomal enzymes in the liver.a 111
Elimination Route
Excreted in urine, principally as unchanged drug (80–90%).100 101 102
Half-life
Conventional oral tablets: 3 hours.100 101 102 110 111
IV: 1.05–1.86 hours.100 101 102 110
Special Populations
Patients with severe myasthenia gravis metabolize and excrete pyridostigmine faster than patients with milder forms of the disease.a
Anephric patients: Half-life 6.3 hours;102 clearance decreased by 75%.111
Geriatric patients (71–85 years of age): Plasma clearance decreased 30%, but half-life is unchanged.111
No information available on pyridostigmine pharmacokinetics in patients with hepatic impairment.111
Stability
Storage
Oral
Conventional 60-mg Tablets and Extended-release Tablets
25°C (may be exposed to 15–30°C).123
Do not store in moist environments (e.g., bathrooms, kitchens).g Hygroscopic; tablets may become mottled, but this does not affect potency.a 123 g
Conventional 30-mg Tablets for Military Use
2–8°C; protect from light.111 Discard unrefrigerated unit-dose packages after 3 months.111
Oral Solution
25°C (may be exposed to 15–30°C).123 Protect from light.a
Parenteral
Injection
25°C (may be exposed to 15–30°C). Protect from light.124 124
Compatibility
For information on systemic interactions resulting from concomitant use, see Interactions.
Drug Compatibility
Compatible |
Heparin sodium |
Hydrocortisone sodium succinate |
Potassium chloride |
Vitamin B complex with C |
Compatible |
Glycopyrrolate |
ActionsActions
Analog of neostigmine, but pyridostigmine may have a longer duration of action and fewer adverse GI effects.a 123 124
Reversibly inhibits acetylcholinesterase, thereby prolonging and exaggerating the effects of acetylcholine.111 117 118 120 121 a Has direct cholinomimetic effect on skeletal muscle.a
Produces generalized cholinergic responses including miosis, bradycardia, increased tonus of intestinal musculature, constriction of bronchi and ureters, and stimulation of secretion by salivary and sweat glands.a
At sufficiently high dosage, directly blocks action at autonomic ganglia, causes CNS stimulation followed by CNS depression and, ultimately, depolarization block.a
Blocks nerve agent soman from access to acetylcholinesterase active sites, protecting the enzyme from irreversible inhibition.111 117
Advice to Patients
Patients with myasthenia gravis: importance of carefully following prescribed dosage instructions.g Importance of recording response to each dosage, especially when initiating therapy or during times of disease instability, to assist clinician with prescribing dosage adjustments.g
Advise military personnel to take pyridostigmine as directed by chain of command for preexposure prophylaxis for possible soman poisoning; advise not to take pyridostigmine immediately before (when attack alarm is given), during, or after exposure to soman.111 f Importance of discontinuing pyridostigmine and following instructions provided in pyridostigmine patient information for treatment (e.g., atropine, pralidoxime) if soman poisoning occurs.f
Military personnel: Importance of discarding 30-mg tablets 3 months after date of issue.f
Advise military personnel that pyridostigmine alone is not protective against soman poisoning; the primary means of protection against nerve agent exposure is wearing protective garments (e.g., masks, hoods, overgarments) designed for this use.111 f
Advise military personnel that if they experience serious adverse effects (e.g., difficulty breathing, severe dizziness, loss of consciousness), to temporarily discontinue the drug and immediately seek medical care.111
Importance of informing clinician of any allergy to bromide or anticholinesterase drugs.f
Importance of informing clinician of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses.a f
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.a
Importance of informing patients of other important precautionary information. (See Cautions.)
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Pyridostigmine bromide 30-mg tablets are for military use only.111
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Oral | Solution | 60 mg/5 mL | Mestinon Syrup (with alcohol 5%) | Valeant |
Tablets | 60 mg* | Mestinon (scored) | Valeant | |
Pyridostigmine Bromide Tablets | Global, Sandoz | |||
Tablets, extended-release | 180 mg | Mestinon Timespan (scored) | Valeant | |
Parenteral | Injection | 5 mg/mL | Regonol (with benzyl alcohol) | Sandoz |
Comparative Pricing
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
Mestinon 180MG Controlled-release Tablets (VALEANT): 30/$137.99 or 90/$380.97
Mestinon 60MG Tablets (VALEANT): 30/$88.99 or 90/$238.97
Pyridostigmine Bromide 60MG Tablets (SANDOZ): 30/$21.99 or 90/$49.97
Disclaimer
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions February 2008. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
References
100. Benet LZ, Oie S, Schwartz JB. Design and optimization of dosage regimens; pharmacokinetic data. In: Hardman JG, Limbird LE, Molinoff PB et al., eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1995:1707-92.
101. Aquilonius SM, Hartvig P. Clinical pharmacokinetics of cholinesterase inhibitors. Clin Pharmacokinet. 1986; 11:236-49. [IDIS 217475] [PubMed 3524957]
102. Cronnelly R, Stanski DR, Miller RD et al. Pyridostigmine kinetics with and without renal function. Clin Pharmacol Ther. (IDIS 124818)
103. American Academy of Pediatrics Committee on Fetus and Newborn and Committee on Drugs. Benzyl alcohol: toxic agent in neonatal units. Pediatrics. 1983; 72:356-8. [IDIS 175725] [PubMed 6889041]
104. Anon. Benzyl alcohol may be toxic to newborns. FDA Drug Bull. 1982; 12(2):10-1. [PubMed 7188569]
105. Centers for Disease Control. Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982; 31:290-1. [IDIS 150868] [PubMed 6810084]
106. Gershanik J, Boecler B, Ensley H et al. The gasping syndrome and benzyl alcohol poisoning. N Engl J Med. 1982; 307:1384-8. [IDIS 160823] [PubMed 7133084]
107. Menon PA, Thach BT, Smith CH et al. Benzyl alcohol toxicity in a neonatal intensive care unit: incidence, symptomatology, and mortality. Am J Perinatol. 1984; 1:288-92. [PubMed 6440575]
108. Anderson CW, Ng KJ, Andresen B et al. Benzyl alcohol poisoning in a premature newborn infant. Am J Obstet Gynecol. 1984; 148:344-6. [IDIS 181207] [PubMed 6695984]
109. ICN Pharmaceuticals. Mestinon (pyridostigmine bormide) syrup, tablets and timespan caplets prescribing information (dated Aug 2000). In: Physician’s Desk Refence electronic library. From PDR web site.
110. Breyer-Pfaff U, Maier U, Brinkmann AM et al. Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis. Clin Pharmacol Ther. 1985; 37:495-501. [IDIS 200487] [PubMed 3987173]
111. Defense Supply Center. Pyridostigmine bromide tablets prescribing information. Philadelphia, PA; 2003 Feb.
112. Agency for Toxic Substances and Disease Registry. Medical Management Guidelines for Nerve Agents: Tabun (GA); Sarin (GB); Soman (GD); and VX. From the CDC website. Accessed Nov 12, 2001.
113. DeLorenzo RA. Exposed: signs, symptoms & EMS management of nerve-agent poisoning. J Emerg Med Serv JEMS. 2001; 26:48-57. [PubMed 11409202]
114. In Ellenhorn MJ, Schonwald S, Ordog G, Wasserberger J, eds. Ellenhorn’s medical toxicology: diagnosis and treatment of human poisoning. 2nd ed. Baltimore: Williams & Wilkins; 1997:1267-90.
115. Marino MT, Schuster BG, Brueckner RP et al. Population pharmacokinetics and pharmacodynamics of pyridostigmine bromide for prophylaxis against nerve agents in humans. J Clin Pharmacol. 1998; 38:227-35. [IDIS 403655] [PubMed 9549661]
116. Keeler JR, Hurst CG, Dunn MA. Pyridostigmine used as a nerve agent pretreatment under wartime conditions. JAMA. 1991; 266:693-5. [IDIS 283899] [PubMed 2072481]
117. Pellegrini JE. The effect of oral pyridostigmine bromide nerve agent prophylaxis on return of twitch height in persons receiving succinylcholine. Milit Med. 2000; 165:252-5.
118. Arad M, Roth A, Zelinger J et al. Safety of pyridostigmine in hypertensive patients receiving beta blockers. Am J Cardiol. 1992; 69:518-22. [IDIS 291776] [PubMed 1346558]
119. Schumm WR, Reppert EJ, Jurich AP et al. Pyridostigmine bromide and the long-term subjective health status of a sample of over 700 male reserve component gulf war era veterans. Psychol Rep. 2002; 90:707-21. [PubMed 12090498]
120. Gouge SF, Daniels D, Smith CE. Exacerbation of asthma after pyridostigmine during Operation Desert Storm. Milit Med. 1994; 159:108-11.
121. In Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, eds. Goldfrank’s Toxicologic Emergencies. 7th ed. New York: McGraw-Hill; 2002:1527-51.
122. Leikin JB, Thomas RG, Walter FG et al. A review of nerve agent exposure for critical care physicians. Crit Care Med. 2002; 30:2346-54. [IDIS 490747] [PubMed 12394966]
123. Valeant Pharmaceuticals International. Mestinon (pyridostigmine bromide) syrup, tablets, and Timespan tablets prescribing information. Costa Mesa, CA; 2005 Jul. From the DailyMed website. Accessed Jun 28, 2007.
124. Sandoz Inc. Regonol (pyridostigmine bromide) injection prescribing information. Broomfield, CO; 2005 Mar.
125. Gunn VL, Nechyba C, eds. The Harriet Lane handbook: a manual for pediatric house officers. 16th ed. Philadelphia, PA: Mosby; 2002:827.
a. AHFS drug information 2007. McEvoy GK, ed. Pyridostigmine bromide. Bethesda, MD: American Society of Health-System Pharmacists; 2007:1249-52.
e. Stockley IH, editor. Stockley's drug interactions. 6th edition. Chicago, IL: Pharmaceutical Press; 2002.
f. Defense Supply Center. Pyridostigmine bromide tablets patient information. Philadelphia, PA; 2003 Feb.
g. Valeant Pharmaceuticals International. Mestinon(pyridostigmine bromide) syrup, tablets, and Timespan tablets product information. From the Valeant website. Accessed Jun 28, 2007.
HID. Trissel LA. Handbook on injectable drugs. 14th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2007:1433-4.
More Pyridostigmine Bromide resources
- Pyridostigmine Bromide Side Effects (in more detail)
- Pyridostigmine Bromide Use in Pregnancy & Breastfeeding
- Drug Images
- Pyridostigmine Bromide Drug Interactions
- Pyridostigmine Bromide Support Group
- 12 Reviews for Pyridostigmine Bromide - Add your own review/rating
- Pyridostigmine Prescribing Information (FDA)
- Mestinon MedFacts Consumer Leaflet (Wolters Kluwer)
- Mestinon Prescribing Information (FDA)
- Mestinon Concise Consumer Information (Cerner Multum)
- Regonol Prescribing Information (FDA)
Compare Pyridostigmine Bromide with other medications
- Dysautonomia
- Myasthenia Gravis
- Nerve Agent Pretreatment
- Reversal of Nondepolarizing Muscle Relaxants
No comments:
Post a Comment